Liver plays a vital role
in human health, and has functions of nutritional metabolism, synthesis,
detoxification, haemopoiesis, immunity and others, which is of great significance
to human health. However,the occurrence of liver damage is often silent and
imperceptible,so the liver is called the silent organ.According to the data of WHO,
more than one million people died from liver disease worldwide every year, and China
is a big liver disease country with heavy burden of viral hepatitis and large
number of chronic viral hepatitis patients. Liver cancer is kind of malignant
tumour with high incidence around the world.The liver cancer patient population
of China accounts for more than half of the world.For such a silent organ as
the liver,physical examination and screening is the key to discover liver
disease and conduct early diagnosis and early treatment. It is the 11th World Hepatitis
Day on July 28,2021 identified by WHO. Governments at all levels, experts
on liver disease and public health, are actively exploring new ways to prevent
and control liver disease, and to achieve the WHO's goal of eliminating viral
hepatitis by 2030 as soon as possible.On July 16, fatty liver and alcoholic
liver disease group of Chinese Society of Hepatology of Chinese Medical
Association,China Liver Health,Meinian Onehealth Healthcare(Group) Co., Ltd.,
Wuxi Health Care Medical Technology Co.,Ltd., Beijing CR Beimao co.,Ltd. signed
the Blue Book of Liver Health of Physical Examination Population in
China(referred to as Blue Book) and strategic cooperation agreement of Joint Health Union on Liver
Health Screening and Diagnosis&treatment of China Project (referred to as
Joint Health Union). The five organizations aim to integrate resources to
regularly release the Blue Book based on the massive liver health data of
physical examination population, so as to arouse public attention to liver
health and provide reference for national public health policy. The
organizations will build a joint health union linking the liver health
screening of physical examination centers and the diagnosis and treatment of
liver disease in public hospitals, move liver health from clinical diagnosis
and treatment to health screening, and provide innovative plans for the
prevention and treatment of liver disease in China.
At the startup meeting of Joint Health Union
on July 16, 2021 At the meeting, Zhuang Hui, academician of Chinese Academy of Engineering, professor
of School of Basic Medical Sciences Peking University, prof. Wei Lai, chief of fatty
liver and alcoholic liver disease group of Chinese Society of Hepatology of
Chinese Medical Association, vice chairman of Beijing Tsinghua Changgung Hospital, prof. Xu Xiaoyuan, director of Chinese Society of Hepatology of Chinese Medical
Association,professor of infectious disease department
of Peking University First
Hospital,prof.Nan Yuemin, director of Chinese Society of
Hepatology of Chinese Medical Association, director of traditional Chinese and western medicine hepatopathy
department of The Third Hospital of Hebei
Medical University, prof. Zhao Jingmin, vice chief of fatty liver and
alcoholic liver disease group of Chinese Society of Hepatology of Chinese
Medical Association,director of Pathological Diagnosis and Research Center of
the Fifth Medical Center of the PLA General Hospital, prof.
Mi Yuqiang, vice chief
of fatty liver and alcoholic liver disease group of Chinese
Society of Hepatology of Chinese Medical Association, vice chairman of Tianjin
Second People’s hospital,Li Mingyang,director of
China Liver Health,Shao Jinhua,general manager of Wuxi
Health Care Medical Technology Co.,Ltd.,Jiang Ying,senior vice
president of Meinian Onehealth Healthcare(Group) Co., Ltd.,
Hu Ning,assistant general manager of prescription drug department of China Resources Sanjiu Medical and Pharmaceutical Co.,
Ltd. attended the meeting and delivered speeches on the health
management and physical examination condition of Chinese people.
At the startup meeting of Joint Health Union
on July 16, 2021 The Proportion of Professional Liver Health Screening
In Physical Examination of China Physical examination is a necessary means for the screening,early diagnosis
and early treatment of liver diseases. With the improvement of the national
economic and public health awareness, the number of health examination in China
has increased in recent years. According to China Health Statistics Yearbook,
the number of health examination in China had increased from 406 million in 2017
to 444 million in 2019. The coverage rate of physical examination in China was
about 31.71% in 2019. According to the relevant data disclosed by Sullivan, the
coverage rate of physical examination in developed countries such as the United
States and Japan had exceeded 70% as early as 2017, and the date of Germany had
exceeded 95%.High coverage of physical examination promotes the early detection
of disease and the improved survival rate of cancer patients.In Japan,
according to the 5-year survival rate and 10-year survival rate released by the
Japanese National Cancer Research Center in 2020, the 10-year survival rate of
cancer patients diagnosed from 2004 to 2007 was 58.3%, the 5-year survival rate
of cancer patients diagnosed from 2010 to 2012 was 68.8%. Even in malignancies
like liver cancer with poor prognosis, Japanese liver cancer patients still
have a 5-year survival rate of 38.1% and a 10-year survival rate of 18.1%.
However, the 5-year survival rate of Chinese liver cancer patients is only 14.1%,
and the early diagnosis rate of liver cancer is only 23.2%, significantly lower
than that in Japan.In view of this situation, prof. Wei Lai, chief of fatty liver
and alcoholic liver disease group of Chinese Society of Hepatology of Chinese
Medical Association revealed the reason. According to his speech, liver health
screening in China covered a relatively small population, the advanced
professional testing technology was underused, the early liver fibrosis was not
detected and dealt with in time, only advanced liver diseases such as liver
cirrhosis, liver cancer can be diagnosed and then conducted with treatment.
According to a WHO report,
there were 910,000 new cases of liver cancer worldwide in 2020, while China
accounted for 410,000, with the largest incidence of liver cancer in the
world."Liver is the most important biochemical organism of human body, and
it has a series of functions such as metabolism, synthesis and
detoxification.Liver health is important to human health.”said Nan Yuemin, director
of Chinese Society of Hepatology of Chinese Medical Association, liver diseases are
great threats to other organs, systems, and even life of people.For
example,fatty liver disease is often combined with cardiovascular disease,
hyperlipidemia, hypertension, diabetes and gout. Patients with hepatitis B and hepatitis
C may suffer from human kidney disease, immune system diseases and
hematopoietic dysfunction.Therefore, it is urgent to actively carry out
professional liver health screening, find various liver diseases with
significant liver fibrosis, and conduct the diagnosis and treatment of the
relevant groups.
At the startup meeting of Joint Health Union
on July 16, 2021 Five Organizations Cooperated to Establish a Joint Health Union On Liver
Health Screening And Diagnosis&Treatment In order to enhance the
public's attention to liver health and strengthen early screening and diagnosis
of liver diseases, the five organizations will regularly release the Blue Book,
and jointly develop the Joint Health Union. The Blue Book, based on the
liver health data of tens of millions people, will reveal the research of cross-sectional study and cohort study
on physical examination people of different ages,different
occupations and different areas, include elasticity values,serum indicators and
basic information of the people, ant reflect the liver health status and
dynamic changes of Chinese people. At the same time, the Joint Health Union
aims to build the connection between Meinian health physical examination
institutions and fatty liver center with hundreds of public hospitals around
the country, to realize the standard and systematic screening, diagnosis and
treatment of liver diseases , to provide convenient treatment ways for the
people with abnormal liver health indicators found out in physical examination,
and to promote the domestic liver health with turning from disease diagnosis
and treatment to health prevention.
"Compared with the
other medical associations, the Joint Health Union pays more attention to
health" Prof. Wei Lai said. The early prevention is the key to realize the
goal of eliminating the hepatitis threat proposed by the country and WHO. This
is the purpose for fatty liver and alcoholic liver disease group of Chinese
Society of Hepatology of Chinese Medical Association to cooperate with public welfare organization,professional physical
examination institution,liver detection technical company and professional
pharmaceutical company.Prof. Wei Lai said that,centering on the big goal of
Healthy China, the project will be based on three platforms.The first is the
professional liver disease treatment platform composed of fatty liver disease
centers of one hundred of grade A hospitals.The second is more than 600 Menian
health examination centers that can provide professional liver health screening.
The third is the liver detection technical platform with liver elasticity
technology and suitable for wide application in liver health screening, which
can be used as the basis for clinical diagnosis and treatment.
"From the perspective of
big health, the project aims to integrate the data of the large population of
China , and innovatively realizes the cross-border cooperation of medical
services, physical examination, detection and drug treatment." said Li
Mingyang, director of Zhonglian Liver Health Promotion Center. He also said
that the project has actively promoted the early prevention of liver disease in
China, and promoted the liver health work to a new height beyond the scope of
medical diagnosis and treatment.
As the initiators of the
project, the five organizations will give full play to their advantages to
promote the construction of Joint Health Union. Wuxi Health Care
Medical Technology Co.,Ltd,, as a leading liver non-invasive testing medical
equipment company in the world, will provide technical support for physical
examination and medical institutions in liver health screening, diagnosis and
tracking evaluation.It is known that iLivTouch product of the company use the
advanced instantaneous elastic imaging technology, which can acquire LSM and
UAP values that reflect the liver fibrosis and liver fat in a noninvasive,
fast, quantitative and accurate way. It provides an important reference for the
screening, diagnosis and evaluation of liver health.At present, the technique
has been recommended by the WHO, American Association for the Study of Liver Diseases, Asia Pacific Liver Disease Society,
and the Guidelines for the Diagnosis and Treatment of Liver
Disease by the Chinese Medical Association. The relevant products have also
been applied in the health management centers and clinical departments of
thousands of medical institutions in China.
As a leading professional health examination and health information
institution in China, Meinian Onehealth Healthcare(Group) Co., Ltd. has many
advantages, such as professional physical examination, authoritative data accumulation,
huge volume of physical examination, and scientific management and
operation.The company has more than 600 physical examination centers in more
than 300 cities across the country, and conduct physical examination for 30
million people every year. The company will make full use of the core function
of big data monitoring to provide authoritative data support for the whole
project. Moreover, as a "Value top 100
" and "Jinniu top 100" enterprise of listed companies in China, China Resources Sanjiu Medical and Pharmaceutical
Co., Ltd. will also actively give full play to the social responsibilities of
pharmaceutical enterprises in the project, and increase the research, development
and production of prescription drugs for liver diseases. It is known that the product
research and development keynotes of the company include two main lines of self-diagnosis
and treatment and prescription medicine.At present, the company is increasing
product research and development and pipeline layout in the fields of hepatitis
B, primary bile liver cirrhosis, liver fibrosis, liver cancer and other liver
diseases.In addition to that, the company is also actively building an
education platform for liver diseases, and simultaneously strengthening the
liver health education among doctors, patients and the public. Academician Zhuang Hui from Chinese Academy
of Engineering said: " Outline of the 14th Five-Year Plan for National
Economic and Social Development and Vision 2035 put forward to safeguard
people's health in priority development strategic position, adhere to the
policy of prevention, further implementation of health China action, improve
the national health promotion policy and national public health protection network,
to provide people with all-life health services. The launch of this project is
an important innovative measure to participate in the Healthy China Action and
implement the medium and long-term plan for the prevention and treatment of
chronic diseases.It is also an important action to truly implement liver health
management.From the liver health early screening, early diagnosis, early
treatment, five organizations reached a strong Joint Health Union, which will
effectively promote the liver disease from passive treatment to active
prevention, achieve more standardized diagnosis and treatment, and eventually
contribute to the prevention of liver disease in China as well as Healthy China
Action. |
关注官方微信 
